SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
More News: Covid Vaccine | COVID-19 | Health Management | Internal Medicine | Norvir | SARS | Study | Vaccines | Virology